Research trends and performance of endothelin A receptor antagonist in kidney care: a bibliometric analysis

BACKGROUND

Endothelin A receptor antagonists (ERAs) have emerged as pivotal therapeutic agents in managing pulmonary hypertension (PH) and various kidney disorders, including chronic kidney disease (CKD) and proteinuric glomerular diseases such as IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS). Although initially developed for pulmonary applications, recent research has highlighted their renoprotective effects, expanding their role in nephrology. This study presents a comprehensive bibliometric analysis of global research trends, key contributors, and emerging applications of ERAs in kidney care over the past three decades.

METHODS

A bibliometric analysis was performed using the Science Citation Index Expanded database (1992-2023). Relevant kidney-related publications were identified through specific keyword searches. Author performance was assessed using the Y-index.

RESULTS

ERA-related research has shown significant growth, particularly in nephrology. The United States and the University of Groningen lead in publication volume and international collaborations, with H.J.L. Heerspink emerging as a key contributor. While PH remains the dominant research focus, nephrology applications are rapidly increasing, particularly in CKD, diabetic nephropathy (DN), and glomerular diseases. A major milestone was the accelerated FDA approval of sparsentan for IgAN in 2023, followed by full approval in 2024 based on confirmatory efficacy data. However, challenges such as fluid retention and cardiovascular risks remain, necessitating further investigation into optimized ERA therapies, including combination strategies with SGLT2 inhibitors.

CONCLUSIONS

The expanding role of ERAs in nephrology underscores their potential in treating proteinuric kidney diseases. Ongoing international collaborations are advancing research on ERA safety, efficacy, and novel therapeutic strategies, supporting their broader clinical application.

The role of endothelin receptor antagonists in kidney disease

Kidney diseases are among the most prevalent conditions worldwide, impacting over 850 million individuals. They are categorized into acute kidney injury and chronic kidney disease. Current preclinical and clinical trials have demonstrated that endothelin (ET) is linked to the onset and progression of kidney disease. In kidney diseases, pathological conditions such as hyperglycemia, acidosis, insulin resistance, and elevated angiotensin II levels lead to an increase in ET. This elevation activates endothelin receptor type A, resulting in harmful effects like proteinuria and a reduced glomerular filtration rate (GFR). Therefore, to slow the progression of kidney disease, endothelin receptor antagonists (ERAs) have been proposed as promising new therapies. Numerous studies have demonstrated the efficacy of ERAs in significantly reducing proteinuria and improving GFR, thereby slowing the progression of kidney diseases. This review discusses the mechanisms of action of ERAs in treating kidney disease, their efficacy and safety in preclinical and clinical studies, and explores future prospects for ERAs.

Real-world assessment of sparsentan's drug safety framework

BACKGROUND

Sparsentan has been approved for reducing proteinuria in adult patients with primary IgA nephropathy (IgAN) at risk of rapid disease progression, yet comprehensive studies evaluating its drug safety framework are lacking.

METHODS

Adverse event (AE) reports following the market release of sparsentan were collected from the U.S. Food and Drug Administration AE Reporting System. Disproportionate analysis was used to identify previously unrecognized positive novel signals at both the system organ class and preferred term levels. Additionally, analysis on clinical priorities and subgroup analysis were conducted.

RESULTS

A total of 504 patients with IgAN were included. Two novel system organ classes and 14 novel preferred terms were identified. Hypotension and dizziness were established as moderate clinical priority events. Males had a higher relative risk of nausea, peripheral edema, feeling abnormal, decreased blood pressure, and hypotension, while females were at greater risk for fatigue, pain, increased blood creatinine, dizziness, and somnolence. Among those aged 18-45, the relative risk of experiencing fatigue, pain, and dizziness was higher, individuals aged 45 and older had a higher relative risk of peripheral edema, decreased blood pressure, and hypotension.

CONCLUSIONS

Based on the available AE reporting data, sparsentan exhibits a favorable safety profile, with no high-priority clinical events identified. Our findings offer valuable insights to optimize the use of sparsentan and understand its potential side effects.

Recurrent acute pancreatitis as an initial presentation of primary hyperparathyroidism in juvenile patient

Acute pancreatitis recurrence should always alert clinicians to primary hyperparathyroidism, especially in younger patients and those with a hereditary condition. When parathyroid abnormalities are adequately recognized and addressed, more recurrent attacks of acute pancreatitis are unlikely to occur.

Contribution of the glomerular filtration rate slope to the kidney hierarchical composite endpoint

INTRODUCTION

A recent chronic kidney disease (CKD) progression hierarchical composite endpoint (HCE) utilizes the glomerular filtration rate (GFR) slope for participants without a dichotomous event. Here, we evaluated clinical interpretations when HCE analyses are driven by GFR slope comparisons.

METHODS

Using CKD trial data, we calculated win odds using only GFR slope; dichotomous kidney events and GFR slope; all-cause mortality, dichotomous kidney events, and GFR slope; and all-cause mortality with dichotomous kidney events.

RESULTS

Win odds (95% confidence interval) calculated from pairwise GFR slope only comparisons were 1.44 (1.34-1.55), 1.60 (1.49-1.72), 1.19 (1.10-1.28), and 0.82 (0.78-0.86) in the DAPA-CKD, CREDENCE, SONAR, and ALTITUDE trials, respectively. Win odds were similar for the GFR slope only and full kidney HCE with and without mortality.

CONCLUSIONS

These results support incorporation of GFR slope into the CKD progression HCE and help to interpret the magnitude of treatment effect on kidney HCE estimated with win odds.

Endothelin-1 signaling in the kidney: recent advances and remaining gaps

The involvement of endothelin-1 (ET-1) in the maintenance of kidney function as well as its role in renal pathophysiology has been appreciated for decades; however, there still exist important gaps in knowledge in our understanding of the mechanistic pathways activated by this system in the kidney. The purpose of this article is to review recent advances in the field, as well as to underscore areas that need more investigation, with an emphasis on the interplay of ET-1 with inflammation, sex differences, circadian rhythms of renal function, the most recent clinical trials involving the ET-1 system, and the interaction between microRNAs and the ET-1 system.

Obesity-related glomerulopathy: How it happens and future perspectives

Obesity-related glomerulopathy (ORG) is an emerging complication of excess adiposity. Its incidence rises alongside the obesity pandemic. Up to 40% of individuals can be affected by ORG, irrespective of the status of glomerular filtration rate and albuminuria. ORG is a distinct histological diagnosis based on kidney biopsy, showing classical features of an enlarged glomerulus with and without focal segmental glomerulosclerosis in the perihilar region seen with all categories of obesity. About 10% of individuals with ORG may progress to end-stage kidney disease. The invasive nature of kidney biopsy highlights the need for non-invasive biomarkers for improved screening, diagnosis and risk prediction of ORG. These biomarkers may narrow the gaps in the management of ORG by improving: (1) screening, diagnosis and differentiation of ORG from non-ORG conditions; (2) risk prediction and stratification of individuals at risk of progression to end-stage kidney disease including the detection of trajectories of progression; (3) monitoring of treatment safety and effectiveness and (4) development of novel therapeutic targets. In the present review, we discussed the pathophysiology, emerging biomarkers (such as kidney injury molecule-1 [KIM-1], uromodulin, klotho, circulating microRNA-21 [miR-21]) and future treatment strategies (metabolic surgery, sodium-glucose cotransporter-2 inhibitors, incretin-based therapy and non-steroidal mineralocorticoid antagonists) of ORG.

An overview of nutritional factors in the aetiopathogenesis of myocardial fibrosis in great apes

The main cause of mortality in great apes in zoological settings is cardiovascular disease (CVD), affecting all four taxa: chimpanzee (Pan troglodytes), bonobo (Pan paniscus), gorilla (Gorilla spp.) and orangutan (Pongo spp.). Myocardial fibrosis, the most typical histological characterisation of CVD in great apes, is non-specific, making it challenging to understand the aetiopathogenesis. A multifactorial origin of disease is assumed whereby many potential causative factors are directly or indirectly related to the diet, which in wild-living great apes mainly consists of high-fibre, low-carbohydrate and very low-sodium components. Diets of great apes housed in zoological settings are often different compared with the situation in the wild. Moreover, low circulating vitamin D levels have recently been recognised in great apes housed in more northern regions. Evaluation of current supplementation guidelines shows that, despite implementation of different dietary strategies, animals stay vitamin D insufficient. Therefore, recent hypotheses designate vitamin D deficiency as a potential underlying factor in the pathogenesis of myocardial fibrosis. The aim of this literature review is to: (i) examine important differences in nutritional factors between zoological and wild great ape populations; (ii) explain the potential detrimental effects of the highlighted dietary discrepancies on cardiovascular function in great apes; and (iii) elucidate specific nutrition-related pathophysiological mechanisms that may underlie the development of myocardial fibrosis. This information may contribute to understanding the aetiopathogenesis of myocardial fibrosis in great apes and pave the way for future clinical studies and a more preventive approach to great ape CVD management.

Reversible dilated cardiomyopathy caused by primary hyperparathyroidism: A case report

BACKGROUND

Dilated cardiomyopathy (DCM) is a common cause of systolic heart failure, and is the most prevalent type of non-ischemic cardiomyopathy. Primary hyperparathyroidism (PHPT) is characterized by hypercalcemia and excessive secretion of parathyroid hormone (PTH). Generally, PHPT is asymptomatic and is incidentally identified during routine laboratory assessments.

CASE SUMMARY

This case report details a 52-year-old man diagnosed with DCM and refractory hypercalcemia, who presented with clinical manifestations including dyspnea, recurrent anorexia, and abdominal distention. Laboratory investigations indicated an elevated serum PTH level, and the sestamibi scan suggested the presence of a parathyroid adenoma. Hence, the patient underwent a parathyroidectomy, which pathologically confirmed the diagnosis of a parathyroid adenoma. Postoperatively, the patient's hypercalcemia was corrected, the dimensions of the cardiac chambers were reduced, and there was a marked improvement in cardiac function.

CONCLUSION

Our findings emphasize the importance of PTH assessment in patients with DCM and concurrent hypercalcemia.

[Clinical polymorphism of primary hyperparathyroidism in children]

BACKGROUND

Primary hyperparathyroidism (PHPT) in children is quite rare, with a prevalence of 2-5 cases per 100,000 children. Hypercalcemia in PHPT has a negative impact on the gastrointestinal tract, urinary, musculoskeletal and nervous systems. Timely diagnosis of the disease in children is difficult due to its rare occurrence and variety of clinical symptoms.

AIM

To study clinical manifestations of primary hyperparathyroidism in children depending on the degree of hypercalcemia.

MATERIALS AND METHODS

Retrospective observational study with a prospective component 50 patients with primary hyperparathyroidism. All patients underwent a comprehensive laboratory and instrumental study at the Institute of Pediatric Endocrinology, Endocrinology Research Center of Russia in the period 2014-2023.

RESULTS

The clinical manifestations of primary hyperparathyroidism in children are very diverse. Weakness and fatigue were observed in 36% of patients (CI (23; 51)). Frequent manifestations of the gastrointestinal tract were nausea - in 20% (CI (10; 34)), gastritis - in 38%, (CI (25; 53)), duodenogastric reflux - in 24%, CI (13; 38). Hypercalciuria was detected in 64% of patients (CI (49; 77)), urolithiasis - in 36% (CI (23; 51). Complaints of leg pain were observed in 24% of patients (CI (13; 38)) deformity of the lower extremities was present in 20% (CI (10; 34)). 16% of patients had a history of low-traumatic fractures (CI (7; 29)). The median age of onset of the first clinical symptoms of PHPT in children was 13.7 years [10.6; 15.2]. At the time of diagnosis of the disease, 12 patients (24%) had no complaints and were examined due to incidentally detected hypercalcemia (n=3), hypercalciuria (n=1), and detected formations of the parathyroid gland according to ultrasound (n=5), with a family history of multiple endocrine neoplasia syndrome type 1 (n=3). To identify the relationship between the clinical manifestations of PHPT and blood calcium levels, all patients were divided into 3 groups depending on the level of hypercalcemia: mild hypercalcemia - 29 patients, moderate - 16, severe - 5. According to the results of the study, a statistically significant relationship between the presence of individual clinical manifestations of PHPT and the degree of hypercalcemia was not identified, however, a statistical tendency was noted between the presence of individual symptoms of the disease (hypercalciuria, weight loss, vomiting, pain in abdomen, constipation, esophagitis, rib pain, gait disturbance) and blood calcium levels, and a positive association was found between hypercalciuria and hypercalcemia. In addition, it was noted that in patients with severe hypercalcemia, the number of clinical signs is significantly higher than in patients with mild or moderate hypercalcemia.

CONCLUSION

The study demonstrates the variety of clinical manifestations of PHPT, for which doctors of various specialties - pediatricians, gastroenterologists, nephrologists, neurologists, orthopedic traumatologists, can observe children. In the presence of symptoms and diseases such as fatigue, nausea, pain in the legs, deformation of the lower extremities, low-traumatic fractures, urolithiasis, gastritis, it is necessary to examine the level of calcium in the blood in children.

Exploring the causal link between serum 25-hydroxyvitamin D concentrations and idiopathic sudden sensorineural hearing loss: Insights gained from a Mendelian randomization study involving two independent samples

Idiopathic sudden sensorineural hearing loss (ISSNHL) is defined by the rapid onset of hearing impairment without an identifiable etiology. The decreased serum concentrations of 25-hydroxyvitamin D(25(OH)D) was shown to be associated with decreased hearing ability. However, current cross-sectional studies have only demonstrated an association, failing to establish a causal link. Therefore, a comprehensive investigation is necessary to clarify the causal relationship between them. Analysis was done by using largescale genome-wide association analysis(GWAS) summary datasets to give information about the incidence of ISSNHL and genetically predicted serum 25(OH)D levels by a two-sample Mendelian randomization (MR) analysis. Instrumental variables (IVs) were identified as genome-wide significant single-nucleotide polymorphisms (SNPs) with a significance threshold of P < 1 × 10-8 and an independence criterion of r2 < 0.001. The GWAS data on serum 25-hydroxyvitamin D levels comprised 6,896,093 SNPs from 496,949 individuals of European ancestry (exposure variable). Outcome data were derived from another GWAS data, including 16,380,424 SNPs from 1,491 European ISSNHL cases and 196,592 controls. MR-Egger, inverse variance weighted (IVW), weighted median, simple mode, and weighted mode, were used to assess causal effects. Heterogeneity tests, horizontal pleiotropy tests, and the leave-one-out method were applied to evaluated the robustness of the MR analysis results. A total of 117 SNPs were employed as instrumental variables (P < 5 × 10-8). Our results indicated no causal association between serum 25(OH) D levels and the risk of ISSNHL within the European population (IVW; OR = 1.09, 95% CI = 0.81 to 1.48, P = 0.573). Furthermore, the statistical models did not reveal any evidence of heterogeneity or pleiotropy.

G-Protein-Coupled Receptors in Chronic Kidney Disease Induced by Hypertension and Diabetes

Hypertension and diabetes are two common causes of chronic kidney disease. Hypertension can induce renal vascular injury, glomerular damage, podocyte loss, and tubular injury, leading to tubulointerstitial fibrosis. A number of factors influence the regulation of hypertension, among which G-protein-coupled receptors (GPCRs) have been studied extensively because they are desirable targets for drug development. Compared to hypertension, the regulatory effects of GPCRs on hypertensive kidney disease (HKD) are less generalized. In this review, we discussed the GPCRs involved in hypertensive kidney disease, such as angiotensin II receptors (AT1R and AT2R), Mas receptor (MasR), Mas-related G-protein-coupled receptor member D (MrgD), relaxin family receptor 1 (RXFP1), adenosine receptors (A1, A2A, A2B, and A3), purinergic P2Y receptors, and endothelin receptors (ETA and ETB). The progression of HKD is rarely reversed but can be retarded by ameliorating the hypertensive microenvironment in the kidneys. However, simply reducing blood pressure cannot stop the progression of HKD. Diabetic nephropathy (DN) is the most common cause of end-stage renal disease (ESRD), which is a major cause of morbidity and mortality in diabetes. Many GPCRs are involved in DN. Here, we select some well-studied GPCRs that are directly associated with the pathogenesis of DN to illustrate their mechanisms. The main purpose of this review is to provide an overview of the GPCRs involved in the occurrence and progression of HKD and DN and their probable pathophysiological mechanisms, which we hope will help in developing new therapeutic strategies.

Affinity on Demand: A One-Pot Method for Synthesis and Sample Enrichment Using TentaGel-Functionalized Resins

Protein glycation is a nonenzymatic reaction that results in the formation of early glycation products, commonly referred to as Amadori products, which play an important role in diabetes complications. In proteomic research, the analysis of glycated peptides is very challenging due to the low amount of analyte in a biological sample. One of the methods to overcome this is selective enrichment of the sample in the desired analyte. A method for synthesizing functionalized resins with phenylboronic acids has been developed, which allows for the incorporation of different linkers and a variable number of phenylboronic acid moieties, as well as the use of any solid support. Furthermore, the resins are prepared for use in sample enrichment following the completion of the synthesis process and demonstrate a high affinity for glycated peptides. The highest-affinity resin (4PhB-3Lys-TGR) was applied to artificially glycated albumin hydrolyzate and patient serum, and, in addition, it was used in conjunction with a biological sample (i.e., milk) for the selective enrichment of glycated peptides. The bioinformatics analysis provided results that confirmed the high coverage of protein sequences identified in the complex samples based on glycated peptides. This paper presents a novel, fast, simple, and cost-effective one-pot method for the synthesis of functionalized resins, along with a selective method for the enrichment of samples with glycated peptides. We believe that the presented approach is general and, with necessary modifications, could be applied for affinity-based isolation not only of Amadori products but also of carbonyl compounds, thiols, compounds with chelating properties, and others.

Associations of Serum Vitamin D with Sarcopenia in Patients with Chronic Liver Disease: A Population-Based Cross-Sectional Study

The association between vitamin D and sarcopenia in patients with chronic liver disease (CLD) has yet to be conclusively established, particularly in Western populations. We investigated the association between serum 25(OH)D levels and sarcopenia in adult CLD patients in the USA. We conducted a cross-sectional study using data from the National Health and Nutrition Examination Survey III. Weighted logistic regression was used to determine the association between sarcopenia and serum 25(OH)D in participants with CLD. CLD was defined as chronic hepatitis B or C, non-alcoholic fatty liver disease, alcohol-related liver disease, and other liver diseases. A serum 25(OH)D level of less than 75 nmol/L was defined as vitamin D insufficiency. This study included 1402 participants with CLD. The serum 25(OH)D concentration was significantly lower in the sarcopenia group (45.3 nmol/l) compared to the non-sarcopenia group (50.6 nmol/l). The prevalence of vitamin D insufficiency was as high as 91.3% in participants with CLD, and the proportion of vitamin D insufficiency was higher in those with sarcopenia. In the full multivariate model, each 10-nmol/L increase in 25(OH)D concentration was significantly associated with a decreased risk of sarcopenia (OR 0.89; 95%CI 0.79-0.99). Conversely, participants with insufficient vitamin D levels had a significantly increased risk of sarcopenia (OR, 2.07; 95% CI 1.08-4.00). Subgroup analyses suggested a sex difference in the association between vitamin D levels and sarcopenia, with a significant association only observed in females. Restricted cubic spline curves indicated a linear inverse association between serum 25(OH)D concentration and risk of sarcopenia in all participants and in females. Low serum 25(OH)D levels were significantly associated with an increased risk of sarcopenia in individuals with CLD, with the observed gender differences in this association warranting further validation in future studies.

The impact of body mass index on the diagnostic and surgical outcomes in primary hyperparathyroidism

OBJECTIVE

The aim of this study was to investigate the influence of body mass index on the diagnostic and surgical outcomes in patients undergoing parathyroidectomy for primary hyperparathyroidism.

METHODS

A total of 446 patients with primary hyperparathyroidism were divided into four groups according to their body mass index: normal weight (body mass index<25 kg/m2) (n=130), overweight (25≤body mass index<30 kg/m2) (n=166), obese (30≤body mass index<35 kg/m2) (n=112), and morbidly obese (body mass index≥35 kg/m2) (n=38). Perioperative findings were compared between the groups.

RESULTS

The preoperative median parathormone level in the morbidly obese group (204 pg/mL, min:max 72:1,178) was significantly lower than that in the normal-weight (246 pg/mL, min:max 60:4,262) (p=0.026) and obese (251 pg/mL, min:max 74:2,094) (p=0.012) groups. The osteoporosis rate in the normal-weight group (51%) was higher than that in the overweight (35.4%) (p=0.041) and morbidly obese (25%) (p=0.023) groups. The symptomatic hypocalcemia rate in the normal-weight group (10.2%) was significantly higher than that in the obese group (1.8%) (p=0.017).

CONCLUSION

Normal-weight patients with primary hyperparathyroidism have higher blood parathormone values, higher rates of osteoporosis, and postoperative symptomatic hypocalcemia compared to patients with higher body mass index. For this reason, the surgeon should consider the possibility of symptomatic hypocalcemia after undergoing parathyroidectomy for primary hyperparathyroidism in normal-weight cases.

Risk-directed management of chronic kidney disease

The timely and rational institution of therapy is a key step towards reducing the global burden of chronic kidney disease (CKD). CKD is a heterogeneous entity with varied aetiologies and diverse trajectories, which include risk of kidney failure but also cardiovascular events and death. Developments in the past decade include substantial progress in CKD risk prediction, driven in part by the accumulation of electronic health records data. In addition, large randomized clinical trials have demonstrated the effectiveness of sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide 1 receptor agonists and mineralocorticoid receptor antagonists in reducing adverse events in CKD, greatly expanding the options for effective therapy. Alongside angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, these classes of medication have been proposed to be the four pillars of CKD pharmacotherapy. However, all of these drug classes are underutilized, even in individuals at high risk. Leveraging prognostic estimates to guide therapy could help clinicians to prescribe CKD-related therapies to those who are most likely to benefit from their use. Risk-based CKD management thus aligns patient risk and care, allowing the prioritization of absolute benefit in determining therapeutic selection and timing. Here, we discuss CKD prognosis tools, evidence-based management and prognosis-guided therapies.

Advances and challenges in kidney fibrosis therapeutics

Chronic kidney disease (CKD) is a major global health burden that affects more than 10% of the adult population. Current treatments, including dialysis and transplantation, are costly and not curative. Kidney fibrosis, defined as an abnormal accumulation of extracellular matrix in the kidney parenchyma, is a common outcome in CKD, regardless of disease aetiology, and is a major cause of loss of kidney function and kidney failure. For this reason, research efforts have focused on identifying mediators of kidney fibrosis to inform the development of effective anti-fibrotic treatments. Given the prominent role of the transforming growth factor-β (TGFβ) family in fibrosis, efforts have focused on inhibiting TGFβ signalling. Despite hopes raised by the efficacy of this approach in preclinical models, translation into clinical practice has not met expectations. Antihypertensive and antidiabetic drugs slow the decline in kidney function and could slow fibrosis but, owing to the lack of technologies for in vivo renal imaging, their anti-fibrotic effect cannot be truly assessed at present. The emergence of new drugs targeting pro-fibrotic signalling, or enabling cell repair and cell metabolic reprogramming, combined with better stratification of people with CKD and the arrival of nanotechnologies for kidney-specific drug delivery, open up new perspectives for the treatment of this major public health challenge.

Unraveling the Relationship Between Vitamin D and Noncommunicable Diseases: A Systemic Review and Meta-Analysis

BACKGROUND

Subclinical vitamin D insufficiency is frequent in both developing and developed countries. Even after rickets was eliminated in the 1930s by fortifying milk, up to 1 billion people worldwide suffer from subclinical vitamin D deficiency (VDD). Numerous noncommunicable diseases (NCDs), including depression, autoimmune illnesses, diabetes, osteoporosis, and cardiovascular disease, are linked to this deficiency.

METHODOLOGY

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol was applied when conducting a systematic review. Relevant studies published between 2010 and 2023 were found by searching databases such as Web of Science, Scopus, and PubMed. To find correlations between deficiency of vitamin D and NCDs, data was extracted from the studies and analyzed using the Mixed Method Appraisal Tools (MMAT). In meta-analysis data combined from multiple observational Unraveling the Relationship Between Vitamin D and Noncommunicable Diseases-A Systemic Review and Meta-Analysis studies to evaluate the relationship between vitamin D insufficiency and health outcomes. Statistical techniques, such as calculating effect sizes and constructing confidence ranges, are employed to determine combined outcomes and investigate possible causal connections.

RESULTS

Fourteen studies-including cross-sectional studies, prospective cohorts, randomized controlled trials, and longitudinal studies-met the inclusion criteria. Significant correlations among deficiency of vitamin D and a number of NCDs, including anemia, diabetes, hypertension, rheumatoid arthritis (RA), mental health issues, and autoimmune hypothyroidism, were found in the review. The results highlight the prevalence of deficiency of vitamin D worldwide and its detrimental impact on health. In order to lower the risk of numerous NCDs, this review emphasizes the need for greater awareness and possible interventions to maintain appropriate vitamin D levels. A meta-analysis was conducted to investigate the potential causal connections between vitamin D insufficiency and different health disorders. It elucidates the connections between deficient levels of vitamin D and conditions such as mental health disorders, anemia, diabetes, hypertension, and autoimmune diseases. The study prioritizes the examination of temporal correlations, biological plausibility, and the removal of confounding factors to provide support for these associations. While the text acknowledges that experimental data, such as randomized controlled trials, would enhance the argument for causation, it mostly depends on observational studies.

Vitamin D and COVID-19: Clinical Evidence and Immunological Insights

Vitamin D has emerged as a potential modulator of immune responses, sparking interest in its role in COVID-19 susceptibility and clinical outcomes. This review synthesizes current clinical evidence and explores immunological insights into the relationship between vitamin D levels and COVID-19 infection severity. Epidemiological studies indicate an inverse correlation between vitamin D deficiency and an increased risk of severe disease, hospitalization, and mortality in COVID-19 patients. Immunologically, vitamin D exerts regulatory effects on both innate and adaptive immunity, enhancing antimicrobial defense mechanisms, reducing excessive inflammatory responses, and potentially mitigating cytokine storm events observed in severe COVID-19 cases. Despite promising observational data, clinical trials evaluating vitamin D supplementation have shown mixed results, underscoring the need for standardized dosing regimens and patient stratification. Future research should focus on large-scale randomized controlled trials to conclusively determine the therapeutic potential and optimal supplementation strategies for vitamin D in managing COVID-19.

Association Among Vitamin D Receptor Gene Polymorphisms, Metabolic Control, and Inflammatory Markers in Type 2 Diabetes: A Systematic Review and Meta-Analysis

CONTEXT

Single-nucleotide polymorphisms (SNPs) in the vitamin D receptor (VDR) contribute to inadequate metabolic profiles in individuals with type 2 diabetes mellitus (T2DM).

OBJECTIVE

We sought to elucidate the relationship among SNPs in the VDR and markers for glycemic control, lipid profile, and inflammation in individuals with T2DM.

DATA SOURCES

We performed a systematic search in the MEDLINE (via PubMed), EMBASE, and SCOPUS databases in July 2021 and updated the search in October 2023.

DATA EXTRACTION

6 observational studies were selected from the databases, and 1 study was included after checking the reference list. Two authors independently completed the selection and data extraction of studies and population characteristics, the prevalence of SNPs in the VDR, genotyping methods, and laboratory findings, and performed summary statistics of the results.

DATA ANALYSIS

The meta-analyses were performed on 5 studies including 1198 adults with T2DM. The duration of the diabetes diagnosis ranged from 5.0 to 14.7 years. A random-effects model was used to pool the results using a 2-tailed (P < .05). Effect sizes were reported as standardized mean differences (SMDs) and 95% confidence intervals (CIs). Four SNPs in the VDR were identified (Fokl, BsmI, Taql, and Apal) by using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The Fokl SNP was identified in 5 studies and associated with a higher percentage of glycated hemoglobin (HbA1c%) (SMD,  0.41 [95% CI, 0.15-0.67]). The Bsml in 4 studies was associated with higher triacylglycerol (SMD, 0.21 [95% CI, 0.03-0.38]). The Taql SNP was identified in 2 studies and did not show any associations, and the Apal SNP was identified in only 1 study and was not analysed in the meta-analysis.

CONCLUSIONS

Although the studies identified 4 SNPs in the VDR, the results of the meta-analysis allowed us to infer only the association of the SNPs Fokl and Bsml with increased %HbA1c and triacylglycerol levels, respectively, in individuals with T2DM.

SYSTEMATIC REVIEW REGISTRATION

PROSPERO registration number CRD42021268152.

Electrochemiluminescent/colorimetric monitoring 25(OH)D3 based on HOFs-g-C3N4-CeO2 functional composite

Vitamin D, mainly in the active form of 25-hydroxy vitamin D3 (25(OH)D3), participates in blood circulation and plays a vital role in metabolic homeostasis. Herein, an electrochemiluminescent (ECL)/colorimetric dual-analytical biosensing platform based on HOFs-g-C3N4-CeO2 (HCC) composite was developed for 25(OH)D3 detection. In the ECL system, electrochemiluminescence-resonance energy transfer (ECL-RET) occurred utilizing HCC as the ECL donor and gold nanorods (Au NRs) as the acceptor. The binding of the complementary aptamer chain (ssDNA) labeled with Au NRs to the aptamer chain VDBA14 immobilized on the surface of HCC quenched the ECL emission via ECL-RET. After adding the target 25(OH)D3, ECL response was recovered due to the competition for VDBA14 between ssDNA and 25(OH)D3, resulting in the reduction of Au NRs and attenuation of the ECL-RET on the electrode. In the colorimetric system, VDBA14 immobilized on magnetic beads (MBs) captured ssDNA tagged with HCC through complementary base pairing. VDBA14 could specifically recognize 25(OH)D3 to release ssDNA competitively, and then, the released HCC was used as the nanozyme to catalyze the chromogenic reaction between tetramethylbenzidine (TMB) and H2O2. The bimodal analysis showed a good response to 25(OH)D3 in the linear range 20 ~ 80 ng/mL, with detection limits of 15.91 ng/mL (for the ECL system) and 7.28 ng/mL (for the colorimetric system). The proposed dual-analytical biosensor improved the reliability of detecting 25(OH)D3 and performed satisfactorily in practical applications, which is of great significance in immunomodulation, skin physiology, and other important aspects of human health.

Innovative therapeutics for renoprotection: Where we are

Chronic kidney disease (CKD) has become highly prevalent worldwide, with major implications for public health, including increased risk of progression to kidney failure, cardiovascular events, and mortality. Up to a decade ago, renin-angiotensin system inhibitors, that is angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers, were the only available pharmacological interventions to slow kidney function loss and limit the associated cardiovascular morbidity and mortality in this context. More recently, landmark trials have demonstrated the ability of novel therapeutics to significantly ameliorate kidney and cardiovascular outcomes in patients with CKD, when added on top of optimized renin-angiotensin system blockade. These include sodium-glucose cotransporter-2 inhibitors in patients with diabetic and nondiabetic kidney disease, as well as the nonsteroidal mineralcorticoid receptor antagonist finerenone and the glucagon-like peptide-1 receptor agonist semaglutide in patients with diabetic kidney disease. We herein review the evolving scenario and the latest evidence for the treatment of CKD, mainly focusing on proteinuric CKD. We started with a presentation of established and more recently approved classes of kidney protective drugs, followed by a discussion of therapeutic interventions under clinical investigation to slow CKD progression. Finally, we underscore the added value of personalized and multidrug interventions, which are becoming increasingly more feasible with the availability of a growing number of kidney protective agents, and are likely to stand as the most powerful tools to safely slow, or even prevent, the progression of proteinuric CKD. SIGNIFICANCE STATEMENT: Chronic kidney disease (CKD) is highly prevalent globally, and is associated with substantial morbidity and mortality. This review provides a comprehensive overview of the currently approved and emerging therapeutic options for the treatment of proteinuric CKD. As novel kidney protective agents have recently become available, the outcomes of patients with CKD could hopefully improve over the few decades ahead.

Micronutrient Deficiencies in Pediatric IBD: How Often, Why, and What to Do?

Inflammatory bowel disease (IBDs), including Crohn's disease (CD), and ulcerative colitis (UC) are complex diseases with a multifactorial etiology, associated with genetic, dietetic, and other environmental risk factors. Children with IBD are at increased risk for nutritional inadequacies, resulting from decreased oral intake, restrictive dietary patterns, malabsorption, enhanced nutrient loss, surgery, and medications. Follow-up of IBD children should routinely include evaluation of specific nutritional deficits and dietetic and/or supplementation strategies should be implemented in case deficiencies are detected. This narrative review focuses on the prevalence, risk factors, detection strategy, and management of micronutrient deficiencies in pediatric IBD.

Efficacy and safety of endothelin receptor antagonists in non-diabetic kidney nephropathy : A systematic review and meta-analysis

BACKGROUND

Recent evidence increasingly confirms the therapeutic potential of endothelin receptor antagonists (ERA) in treating non-diabetic kidney nephropathy. However, clinical data in this area remain limited. Therefore, we conducted this meta-analysis to investigate the efficacy and safety of ERAs in the treatment of non-diabetic kidney nephropathy.

METHODS

Randomized controlled trials were identified through PubMed, WOS, Embase, Cochrane Library and Google scholar. The initial participant characteristics and primary outcome measures were gathered, followed by the calculation of risk ratios (RR) and 95% confidence intervals (CI). Additionally, subgroup analyses were conducted to investigate the sources of heterogeneity.

RESULT

In this study, seven randomized, controlled trials (RCT) were included. The results indicated that patients in the ERAs group exhibited a greater mean reduction in the urinary protein to creatinine ratio (UPCR) (standardized mean difference, MD -28.08, 95% CI -33.59 to -22.57, p < 0.001). The number of patients experiencing either complete or partial remission from proteinuria notably increased when treated with ERAs (complete remission: odds ratio, OR = 3.14, 95% CI 2.23-4.42, p < 0.001; partial remission: OR = 3.03, 95% CI 2.33-3.96, p < 0.001). Furthermore, ERAs delayed the decline in the estimated glomerular filtration rate (eGFR, MD = 3.81, 95% CI 1.71-5.90, p < 0.001). However, the incidence of edema events slightly increased in the ERA group (OR = 1.42, 95% CI 1.04-1.93, p = 0.03).

CONCLUSION

The use of ERAs is more effective than regimens without ERAs in slowing the progression of non-diabetic nephropathy.

Primary Hyperparathyroidism: An Analysis Amid the Co-Occurrence of Type 2 Diabetes Mellitus

BACKGROUND

Apart from classical elements in primary hyperparathyroidism (PHPT), non-classical complications, including type 2 diabetes mellitus (T2DM), are reported in some patients, but currently, they do not represent a parathyroidectomy (PTx) indication.

OBJECTIVE

to explore the latest data regarding glucose profile, particularly, T2DM and metabolic syndrome (MetS) in PHPT, including post-PTx.

METHODS

PubMed-based review included English-published original studies between January 2020 and December 2024 (n = 20).

RESULTS

Studied population: 764,485 subjects (female-to-male ratio of 1.26:1; 23,931 were PHPT patients vs. 740,502 controls). T2DM prevalence (n = 13; N = 763,645 patients; 55.92% females): 4-60% (higher vs. controls); for the largest study (N = 699,157) of 31.3%. Age-based analysis: higher T2DM prevalence at >50 vs. <50 years (14.4% vs. 2.6%, p < 0.001), but not all studies agreed. Concurrent vitamin D deficiency as a contributor to a higher risk had limited evidence. The association MetS-PHPT (n = 2) had no clear conclusion. Post-PTx showed the following: lower glycaemia, fasting insulin, insulin resistance (HOMA-IR) improvement, and reduced rate (but not all studies agreed). PHPT patients with prediabetes might represent the population sub-group with the highest post-PTx benefit.

CONCLUSIONS

The panel of PHPT-T2DM interplay remains heterogeneous. Data regarding post-PTx improvement of glucose disorders are still conflicting, recent findings suggested that surgery has beneficial effects, especially in patients with confirmed pre-existing prediabetes. Patients with the normocalcemic variant seemed to be less affected by the glucose-related disturbances, but further studies are needed. A better understanding of the intricate relationship between PHPT and glucose metabolism anomalies will help in providing optimal management to reduce the overall disease burden.

The Impact of Mechanical Circulatory Support Devices on White Blood Cell Phenotype and Function

BACKGROUND

Mechanical circulatory support devices (MCSDs) have gradually become an effective treatment of end-stage heart failure (HF). However, the introduction of foreign surfaces and non-physiological shear stress (NPSS) can cause severe damage to various blood cells, leading to impaired function of immune system and increased risk of complications such as inflammation and thrombosis. The effect of mechanical injury on white blood cell (WBC) has been largely neglected compared to that on red blood cell (RBC) and platelet (PLT).

METHOD

To better understand the impact of MCSDs on WBCs and emphasize the importance of investigating WBC damage to avoid adverse events during mechanical circulatory support, this review elaborated the induction of WBC phenotypic and functional injury by MCSD-related factors, and the relationship between injury and clinical complications. Furthermore, this article provided a detailed review and comparative analysis of in vitro blood-shearing devices (BSDs) and detection methods used in WBC damage investigation.

RESULTS

NPSS, biomaterials and other related factors can activate WBC, decrease WBC function, and promote the release of pro-inflammatory and pro-thrombotic microparticles, increasing the risk of inflammation and thrombotic complications. The evaluation of WBC damage typically involves measuring cell viability and dysfunction using in vitro BSDs (e.g. concentric cylinder devices) and injury detection methods (e.g. flow cytometry).

CONCLUSIONS

WBCs with normal morphology may also experience functional failure due to NPSS from MCSDs, leading to sublethal mechanical cell injury. Therefore, the effect of MCSDs on WBCs can be more comprehensively evaluated by a combination of measuring cell functional capacity and cell counting.

Longitudinal Changes in Peripheral and Alveolar Monocyte and Inflammatory Biomarkers are Distinct in Hypercapnia Patients Following Pulmonary Sepsis-Induced ARDS

Background

Hypercapnia, an Acute Respiratory Distress Syndrome (ARDS) complication after pulmonary sepsis, remains enigmatic in terms of its immunological mechanisms. Our study was designed to compare initial values and longitudinal changes in cellular composition and inflammatory biomarkers between pneumonia sepsis-induced ARDS patients without hypercapnia and hypercapnia patients.

Methods

Between Dec 2022-Apr 2023, we prospectively studied 61 severe pneumonia patients. Eleven non-sepsis pneumonia patients were controls; 50 patients with pulmonary sepsis met ARDS criteria, 26 among them developed hypercapnia. We collected clinical data, respiratory parameters, peripheral blood mononuclear cells (PBMCs), and bronchoalveolar lavage fluid (BALF) at Day 1 and Day 7 post-intubation. Single-cell RNA sequencing (ScRNA-seq) was performed between selected hypercapnia and non-hypercapnia patients to characterize immune and cellular profiles. Specimens were analyzed via flow cytometry and cytokine panel.

Results

By compiling clinical data and specimens, we found that hypercapnia patients with ARDS had poorer outcomes and higher mortality. At day 1, ScRNA-seq and cytometric analysis revealed increase in monocytes and activation of cytokine storm genes with elevated interleukin (IL) -1β, IL-12p40, and IL-23 in peripheral blood. In hypercapnia patients, percentage of CD14+CD16- classical monocyte and concentrations of IL-12p40 and IL-23 increased from day 1 to day 7 in both circulation and airways. However, these alterations of cellular phenotype and cytokine decreased during seven-treatment period in non-hypercapnia patients.

Conclusion

We offer novel perspectives on monocyte-centered clusters and associated biomarkers, which play a pivotal role in driving hypercapnia after pulmonary sepsis-induced ARDS. Our study provides fresh insights into the immunological mechanisms underlying hypercapnia in ARDS, laying the foundation for useful therapeutic targets to improve patient outcomes.

The Optimal Protective 25-Hydroxyvitamin D Level for Different Health Outcomes in Adults: A Brief Summary of Dose-Response Meta-Analyses

Vitamin D is very important for bone metabolism as well as for the prevention of various diseases, such as type 2 diabetes, cardiovascular disease and different types of cancer. Although vitamin D deficiency is widespread and an important public health problem, there exists controversy in the scientific community, with no established standard definition of adequate and deficient vitamin D status. To add new information on this topic, the aim of this brief opinion paper is to identify and discuss the optimal 25(OH)D concentration (range) for a reduction in the risk of various disease outcomes by summarizing dose-response reporting meta-analyses.

Vitamin D Status and Incidence of SARS-CoV-2 Reinfections in the Borriana COVID-19 Cohort: A Population-Based Prospective Cohort Study

A deficient vitamin D (VitD) status has been associated with SARS-CoV-2 infections, severity, and mortality. However, this status related to SARS-CoV-2 reinfections has been studied little. Our aim was to quantify the risk of reinfections considering VitD status before reinfection.

METHODS

We performed a population-based prospective cohort study in Borriana (Valencia Community, Spain) during 2020-2023, measuring 25-hydroxyvitamin D [25(OH)D] levels by electrochemiluminescence. Cox proportional hazards models were employed.

RESULTS

Of a total of 644 SARS-CoV-2 cases with confirmed laboratory tests, 378 (58.9%) were included in our study, with an average age of 38.8 years; 241 were females (63.8%), and 127 reinfections occurred (33.6%). SARS-CoV-2 reinfection incidence rates per 1000 person-days by VitD status were 0.50 for a deficient status (<20 ng/mL), 0.50 for an insufficient status (20-29 ng/mL), and 0.37 for a sufficient status (≥30 ng/mL). Compared with a sufficient VitD status, adjusted hazard ratios were 1.79 (95% confidence interval [CI] 0.89-3.59) for a deficient status and 1.59 (95% CI 1.06-2.38) for an insufficient status with a significant inverse dose-response (p = 0.02). These results can help improve nutritional actions against SARS-CoV-2 reinfections.

CONCLUSIONS

These results suggest that a VitD status lower than 30 ng/mL showed a higher risk of SARS-CoV-2 reinfection. Achieving and maintaining a sufficient VitD status is recommended to prevent reinfections.

Annual Vitamin D Status of World-Class British Swimmers Following a Standardised Supplementation Protocol for Three Years

Background/objectives: British swimmers are at a heightened risk of vitamin D deficiency (serum 25-hydroxyvitamin D (25(OH)D): <50 nmol∙L-1) as their large indoor training volumes often restrict sunlight exposure, especially during the winter when daylight hours are reduced in the United Kingdom. Previous research has recommended supplementation with 4000 IU∙day-1 vitamin D3 from October to March to offset vitamin D losses. However, no current study has analysed this approach over multiple seasons to assess if this is an appropriate strategy. Methods: Using a quasi-experimental design, twenty-nine world-class British swimmers (aged 16-30 years) provided a 10 mL venous blood sample (fasted) as part of their routine haematological screening in the September of three consecutive years (2018, 2019, and 2020). Serum 25(OH)D was determined by radioimmunoassay, and this result determined the length of the standardised vitamin D3 protocol (<30 nmol∙L-1: 4000 IU∙day-1 from September to March; 30-79 nmol∙L-1: 4000 IU∙day-1 from October to March; >75 nmol∙L-1: no supplementation). Results: Mean serum 25(OH)D concentrations increased each year (2018: 76.4 ± 28.4 nmol∙L-1, 2019: 91.5 ± 24.8 nmol∙L-1, 2020: 115.0 ± 36.6 nmol∙L-1, p < 0.001), which coincided with the eradication of vitamin D deficiency after one season (prevalence, 2018: 10%, 2019: 0%, 2020: 0%). In September 2020, 35% of swimmers had a serum 25(OH)D > 125 nmol∙L-1, although it is currently debated whether this is a concern or a benefit for athletic populations. Conclusions: Supplementing with 4000 IU∙day-1 of vitamin D3 throughout the winter can increase the vitamin D status of swimmers. However, more frequent testing may be required to ensure that serum 25(OH)D remains within the sufficient range across the season (75-125 nmol∙L-1).

Elevated Levels of IL-1Ra, IL-1β, and Oxidative Stress in COVID-19: Implications for Inflammatory Pathogenesis

Background: The coronavirus-caused disease (COVID-19), first identified in China in December 2019, has spread worldwide becoming a global pandemic. Although people infected with the SARS-CoV-2 virus presented mainly respiratory and gastrointestinal symptoms, an increase in cardiovascular incidents was observed in several scientific studies. SARS-CoV-2 virus has been shown to disrupt the normal immune response leading to a dysregulation of immune system function and massive production of inflammatory cytokines commonly known as "cytokine storm". Methods: 57 patients eventually participated in the study, assigned to non-COVID (24 patients) and COVID (33 patients) groups. After signing consent to participate in the study, each patient was given a self-administered questionnaire to fill out prior to specimen collection, anthropometric measurements were taken and venous blood was collected for the following determinations: pro- and anti-inflammatory cytokines using a Bio-Plex 200 system, oxidative stress markers and basic hematological blood parameters. Results: showed statistically significant higher values of IL-1Ra and IL-1β in the COVID-19 group. Of the oxidative stress markers, only MDA levels were higher in the COVID-19 group. Conclusions: the results of our study provide evidence and support the occurrence of elevated levels of IL-1Ra, IL-1β and MDA in the COVID-19 group of patients, which are associated with a worse course and prognosis of COVID-19. A better understanding of the pathophysiology and dysregulation of the immune system associated with the cytokine storm is essential to select patients at risk and develop effective drugs and vaccines.

Vitamin D and Chronic Rhinosinusitis with Nasal Polyps: A Narrative Review and Perspectives

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a subtype of chronic rhinosinusitis (CRS) characterized by bilateral nasal polyps, primarily affecting adults. It is often associated with hyposmia and asthma and driven by persistent Th2 inflammation, particularly in Caucasian patients. The disease is recurrent and significantly impacts quality of life, yet its pathophysiology remains poorly understood. Management includes intranasal steroids, short courses of systemic corticosteroids, surgery for refractory cases, and biologics. However, despite these treatment options, disease control remains challenging. Low vitamin D levels have been associated with worse clinical outcomes, while supplementation studies show promise in improving symptoms in deficient patients. Emerging research suggests that vitamin D modulates immunity, fibroblast activity, and epithelial integrity, potentially contributing to CRSwNP pathogenesis, though the exact mechanisms remain unclear. This review synthesizes current research on vitamin D's role in systemic and local inflammation in CRSwNP. By highlighting its potential therapeutic implications, this work aims to guide future research and inform clinical practice. Additionally, it may serve as a foundation for understanding the broader impact of vitamin D deficiency in sinonasal diseases and other atopic conditions.

Endothelin receptor antagonists for diabetic kidney disease: back to the future?

INTRODUCTION

Diabetic kidney disease (DKD) is a leading cause of chronic kidney disease worldwide. Endothelin-1 (ET-1) is a potent vasoconstrictor secreted by vascular endothelial cells, actively involved in the pathophysiology of numerous cardiovascular diseases. Based on the differential downstream effects of ET-1 binding to its two distinct types of receptors (ETA/ETB) within the kidney, selective ETA receptor blockade has been long proposed as a promising treatment modality for DKD.

AREAS COVERED

This review aims to examine the available evidence base for the use of ERAs in the treatment of DKD, by critically reappraising available landmark trials and discussing their possible position in the context of current treatment of this disease.

EXPERT OPINION

Despite early enthusiasm and widespread expectations, endothelin receptor antagonists (ERAs) faded into obscurity following the release of the first randomized controlled trials (RCTs). More recent RCTs using different compounds have re-introduced ERAs as a promising treatment in the growing pharmaceutical armamentarium of DKD. While the future of DKD management will be based on a more personalized approach, new, robust evidence from appropriately designed RCTs is eagerly anticipated to clearly define the role of ERAs in DKD.

Association of Metformin use with risk of dementia in patients with type 2 diabetes: A systematic review and meta-analysis

AIM

There is ongoing debate concerning the association of metformin with the risk of dementia in type 2 diabetes mellitus (T2DM). This study was conducted to evaluate the impact of metformin therapy on dementia in patients with T2DM.

MATERIALS AND METHODS

PubMed, Embase, Cochrane Library, Web of Science and the ClinicalTrials.gov website were searched until 9 April 2024. Cohort studies investigating the effects of metformin therapy compared with other antidiabetic drugs or no therapy in T2DM were included. The hazard ratio (HR) and the 95% confidence interval (CI) were computed using the random effects model.

RESULTS

Twenty cohort studies (24 individual comparisons) involving 3 463 100 participants were identified. A meta-analysis revealed that people with T2DM who take metformin are linked to a lower incidence of all-cause dementia compared to non-user (n = 17, HR = 0.76, 95% CI = 0.65-0.91, p = 0.002, I2 = 98.9%) and sulfonylureas (n = 5, HR = 0.88, 95% CI = 0.85-0.90, p < 0.001, I2 = 9.7%), but not to thiazolidinedione (n = 2, HR = 0.53, 95% CI = 0.08-3.41, p = 0.503, I2 = 92.7%). Additionally, metformin showed favourable effects in non-specified T2DM (n = 19, HR = 0.75, 95% CI = 0.64-0.89), but not in newly diagnosed T2DM (n = 5, HR = 1.01, 95% CI = 0.81-1.27).

CONCLUSION

Metformin might correlate with a lower dementia incidence in people with T2DM. However, it is crucial to interpret these results with caution considering the high heterogeneity.

Aprocitentan for Blood Pressure Reduction in Black Patients

BACKGROUND

Black individuals frequently present with resistant hypertension and disproportionately increased cardiovascular risk. We investigated the blood pressure (BP)-lowering effect of the dual endothelin receptor antagonist aprocitentan in Black individuals enrolled in the PRECISION study (Parallel-Group, Phase 3 Study with Aprocitentan in Subjects with Resistant Hypertension).

METHODS

Patients with confirmed resistant hypertension were randomized to aprocitentan 12.5 mg, 25 mg, or placebo for 4 weeks (part 1). They subsequently received aprocitentan 25 mg for 32 weeks (part 2) before re-randomization to aprocitentan 25 mg or placebo (part 3).

RESULTS

Eighty-two patients randomized in the PRECISION study were Black individuals. At week 4, aprocitentan 12.5 and 25 mg reduced office trough systolic BP (-11.3 and -11.9 mm Hg) to a similar degree as placebo (-12.0 mm Hg). Using 24-hour ambulatory BP monitoring, the placebo effect was minimal (-0.7 mm Hg), and aprocitentan reduced systolic BP by 4.0 and 8.6 mm Hg. During part 2, office BP continued to decrease (-16.4 mm Hg at week 36). In part 3, office and ambulatory systolic BP increased on placebo (+9.9 and +8.1 mm Hg, respectively), whereas the BP-lowering effect was maintained with aprocitentan. Aprocitentan markedly reduced albuminuria during the study. The most frequent adverse event was peripheral edema, occurring in 3 patients (10%) receiving aprocitentan 25 mg versus none receiving aprocitentan 12.5 mg or placebo.

CONCLUSIONS

Aprocitentan reduced BP and albuminuria in Black individuals with resistant hypertension. The BP-lowering efficacy was similar to that of the overall PRECISION population. Aprocitentan may represent an important addition to the often difficult-to-control hypertension in Black individuals.

REGISTRATION

URL: https://www.clinicaltrials.gov; Unique identifier: NCT03541174.

Bridging the Gap Between CKD Management Paradigms in Transplant and Nontransplant Settings: Published Evidence, Challenges, and Perspectives

Kidney transplantation (KT) is the best treatment for patients with kidney failure, associated with improved survival and quality of life compared with maintenance dialysis. However, despite constant improvements in the assessment and management of the alloimmune response, KT patients frequently demonstrate a reduced estimated glomerular filtration rate. Therefore, the usual complications of chronic kidney disease (CKD), such as anemia, hypertension, metabolic acidosis, hyperkalemia, or persistent secondary hyperparathyroidism, are highly prevalent after KT. However, their underlying mechanisms are different in the transplant setting (compared with the nontransplanted CKD population), and management recommendations are based on relatively poor-quality data. In recent years, new therapies have emerged, significantly improving kidney and cardiovascular outcomes of non-KT patients with CKD. Whether those new drugs could improve the outcomes of KT patients has largely been under investigated so far. In this review, we will address the challenges of the management of a KT patient with a reduced estimated glomerular filtration rate, cover the published evidence, and highlight the critical knowledge gaps.

Effects of Deoxynivalenol Contamination on Growth Performance, Blood Biochemistry, Histology, Metabolomics, and the Microbiota: A Subacute Dose Oral Toxicity Study in Rats

Deoxynivalenol (DON), one of the most common mycotoxins, is frequently found in foods. This study investigated the effects of orally administered DON on the blood biochemical parameters, growth performance, histology, microbial composition, and metabolism of rats. After a 1-week adaptation period, 4-week-old rats were administered 0.9% saline (control), 1 mg/L DON (T1), 10 mg/L DON (T2), or 50 mg/L DON (T3) by gavage for 49 days. The DON-treated groups had significantly lower body weights than the control group (p < 0.05). Blood alkaline phosphatase, phosphate, cholesterol, amylase, and creatinine levels differed significantly between the DON-treated and control groups (p < 0.05). With increasing DON doses, fibrosis and apoptosis were observed in several tissues. In terms of metabolites, the bile acid biosynthesis pathway emerged as a potential biomarker, while the tryptophan metabolism pathway was found to be the most affected. The fecal microbiota showed significant differences in both alpha and beta diversity between the DON-treated and control groups (p < 0.05). In the cecal and fecal microbiota, the relative abundance of Firmicutes increased in the control and T1 groups, whereas Bacteroidota and Campylobacterota were more abundant in the T2 and T3 groups. In conclusion, our results showed that high DON exposure induces several dose-dependent adverse effects on rats.

Fibrosis: cross-organ biology and pathways to development of innovative drugs

Fibrosis is a pathophysiological mechanism involved in chronic and progressive diseases that results in excessive tissue scarring. Diseases associated with fibrosis include metabolic dysfunction-associated steatohepatitis (MASH), inflammatory bowel diseases (IBDs), chronic kidney disease (CKD), idiopathic pulmonary fibrosis (IPF) and systemic sclerosis (SSc), which are collectively responsible for substantial morbidity and mortality. Although a few drugs with direct antifibrotic activity are approved for pulmonary fibrosis and considerable progress has been made in the understanding of mechanisms of fibrosis, translation of this knowledge into effective therapies continues to be limited and challenging. With the aim of assisting developers of novel antifibrotic drugs, this Review integrates viewpoints of biologists and physician-scientists on core pathways involved in fibrosis across organs, as well as on specific characteristics and approaches to assess therapeutic interventions for fibrotic diseases of the lung, gut, kidney, skin and liver. This discussion is used as a basis to propose strategies to improve the translation of potential antifibrotic therapies.

Antibiotic-induced gut dysbiosis: unraveling the gut-heart axis and its impact on cardiovascular health

Cardiovascular diseases (CVDs) remain the major cause of morbidity and mortality amongst people of all ages across the world. Research suggests that the initiation and progression of CVDs are associated with antibiotic-induced gut dysbiosis. Antibiotics are primarily intended to be used to treat bacterial infections, which can alter gut microbiota (GM) composition, by lowering the abundance of beneficial bacteria, like Firmicutes, Bacteroidetes, and increasing the profusion of Enterobacteriaceae, leading to harm on gut health. Additionally, it reduces short-chain fatty acids (SCFAs) and bile acid metabolism, increases trimethylamine N-oxide (TMAO) production, intestinal permeability allowing lipopolysaccharide (LPS) and TMAO into systemic circulation. SCFAs play a key role in lipid metabolism, inflammation, and strengthening of the intestinal barrier, and participate in CVDs through FFAR2 and FFAR3 receptors, whereas dysbiosis reduces SCFAs levels and worsens these effects. TMAO enhances oxidative stress, inflammation, endothelial dysfunction, and cholesterol dysregulation, thus worsening CVDs. Furthermore, LPS develops systemic inflammation, insulin resistance, and endothelial dysfunction by activating the NF-κB pathway. Dysbiosis also affects bile acid synthesis, disrupting lipid and glucose metabolism, further participating in the progression of CVDs. This article aims to explore the role of gut dysbiosis in various CVDs, including congenital heart disease, hypertension, valvular heart disease, coronary heart disease, and heart failure. Furthermore, this article aims to bridge the knowledge gap regarding the gut-heart axis by exploring how antibiotics alter the gut microbiota homeostasis, further contributing to the development of CVDs and therapeutic interventions that reduce cardiovascular risks and restore the gut microbiota homeostasis.

Vitamin D: A Nutraceutical Supplement at the Crossroad Between Respiratory Infections and COVID-19

Even though in mid-2023 the World Health Organization declared the end of the public health emergency of international concern status for COVID-19, many areas of uncertainty about SARS-CoV-2 infection pathophysiology remain. Although in the last 4 years pharmaceutical industries widely invested in the development of effective antiviral treatments and vaccines, large disparities in their availability worldwide still exist, thus fostering the investigation of nutritional supplements as adjuvant therapeutic approaches for disease management, especially in resource-limited settings. During the COVID-19 pandemic, vitamin D has been widely used as an over-the-counter solution to improve disease evolution, thanks to its known immunomodulatory and anti-inflammatory actions. Ecological and observational studies support a relationship between hypovitaminosis D and COVID-19 negative outcomes and, according to this evidence, several research groups investigated the role of vitamin D supplementation in protecting from SARS-CoV-2 infection and/or improving disease evolution. This narrative review is intended to offer insights into the existing data on vitamin D's biological effects in respiratory infections, especially in COVID-19. Furthermore, it will also offer a brief overview of the complex interplay between vitamin D and vaccine-elicited immune response, with special attention to anti-COVID-19 vaccines.

Vitamin D in Reproductive Health Disorders: A Narrative Review Focusing on Infertility, Endometriosis, and Polycystic Ovarian Syndrome

Vitamin D (VD) is a fat-soluble steroid hormone with essential physiological functions beyond calcium and bone metabolism. In recent years, its role in women's reproductive health has gained attention, influencing ovarian function, follicular development, endometrial receptivity, and steroid hormone regulation. VD deficiency has been linked to reproductive disorders such as polycystic ovarian syndrome (PCOS), endometriosis, and infertility. Studies indicate that up to 40-50% of healthy pregnant women have insufficient VD levels, which may contribute to adverse pregnancy outcomes and reduced fertility. With growing evidence connecting VD to reproductive health, this review examines its molecular and endocrine mechanisms in fertility, endometriosis, and PCOS. It explores VD's therapeutic potential and its implications for improving clinical approaches and future research in reproductive medicine. Maintaining adequate VD levels is crucial for ovarian function, immune modulation in reproductive tissues, and overall fertility. Its deficiency is associated with insulin resistance, hormonal imbalances, and inflammatory processes, which contribute to reproductive pathophysiology. Establishing reference values for VD in reproductive medicine is essential for optimizing fertility treatments and improving clinical outcomes. This review synthesizes current research on VD's role in reproductive health and highlights the need for further investigation into its therapeutic applications.

Causal association between serum 25-hydroxyvitamin D levels and gestational diabetes mellitus: a bidirectional two-sample Mendelian randomization study

PURPOSE

Previous investigations have assessed the connection between vitamin D deficiency and an increased risk of gestational diabetes mellitus (GDM); however, the findings remain inconsistent. The purpose of this study was to investigate the causal relationship between 25-hydroxyvitamin D (25OHD) levels and GDM.

METHODS

Summary statistics data from genome-wide association studies (GWASs) were used to perform a bidirectional two-sample Mendelian randomization (MR) study. A total of 417,580 Europeans from the UK Biobank provided summary statistics data for 25OHD. The tenth data release of the FinnGen study provided the data for GDM, comprising 14,718 cases and 215,592 controls. For the univariate MR (uvMR) investigations, we employed the inverse variance weighted (IVW) method as our major analytical approach. Multiple sensitivity analyses were performed to evaluate the robustness of the results. Moreover, multivariate MR (mvMR) studies were conducted to account for potential confounding variables, including obesity, insulin resistance, and lipid traits.

RESULTS

In the forward MR study, uvMR analysis did not provide evidence supporting a causal effect of 25OHD levels on the risk of GDM [IVW odds ratio (OR): 1.07, 95% confidence interval (CI): 0.95 to 1.19, p = 0.273]. After adjusting for obesity, fasting insulin levels, and lipid traits, the findings from the mvMR analysis aligned with those of the uvMR analysis. In the reverse MR study, uvMR analysis indicated that GDM had no causal effect on serum 25OHD levels (IVW β = -0.003, p = 0.804), and the robustness of this finding was confirmed in the mvMR study.

CONCLUSION

Our MR research revealed no causal effect of serum 25OHD levels on GDM, suggesting that 25OHD deficiency does not correlate with an increased risk of GDM. Furthermore, our reverse analysis revealed no causal effect of GDM on 25OHD levels.

Adolescent primary hyperparathyroidism

Adolescent primary hyperparathyroidism (PHPT) is a rare endocrine disorder bearing distinctions from the adult form. This review examines its unique aspects, focusing on clinical presentation, genetic etiologies, genotype-phenotype correlations, and therapeutic management. Adolescent PHPT often has a genetic basis, whether familial, syndromic, or apparently sporadic, and identifying the underlying genetic cause is important for patient care. The clinical presentation is predominantly symptomatic worldwide. Unique manifestations in this age group include rickets, short stature, and slipped capital femoral epiphysis. Genotype-specific differences are evident in the adolescent PHPT characteristics. Diagnostic evaluation requires careful interpretation of biochemical and dual-energy X-ray absorptiometry findings using age and gender-specific reference ranges, with targeted screening for syndrome-associated neoplasms. Surgery remains the cornerstone of management. Current knowledge gaps in their management include treatment protocols for multiple endocrine neoplasia type 1-associated PHPT, the efficacy and safety of nonsurgical options, and long-term post-surgical outcomes.

Persistence and Recurrence of Primary Hyperparathyroidism

Persistent and recurrent primary hyperparathyroidism (PHPT) represent significant challenges in the management of PHPT. Persistent PHPT is defined as persistence of hypercalcemia following parathyroidectomy (PTX) or the recurrence of hypercalcemia within the first 6 months following surgery. Recurrent PHPT is defined as recurrence of hypercalcemia after 6 months following PTX and requires normalization of serum calcium prior to the recurrence. These conditions are often attributed to missed or ectopic glands, multiglandular disease, surgeon inexperience, or rare causes such as parathyromatosis and parathyroid carcinoma. Diagnosis requires a detailed biochemical evaluation, imaging studies, and exclusion of other causes of hypercalcemia as well as secondary causes of hyperparathyroidism. Preoperative imaging modalities, including neck ultrasound, SPECT-CT with 99m Tc-sestamibi scan, 4D-CT, 18F-Fluorocholine PET/CT, and PET/MRI are helpful in localizing abnormal parathyroid glands in cases requiring repeat surgery. Repeat surgery is associated with higher risk and requires an experienced surgeon. When surgery is not indicated or possible, medical management with cinacalcet and antiresorptive therapies may be considered. This review highlights the etiology, diagnostic approaches, and management strategies for persistent and recurrent PHPT, emphasizing the importance of multidisciplinary care in order to optimize outcomes.

mTOR pathway: A key player in diabetic nephropathy progression and therapeutic targets

Diabetic nephropathy is a prevalent complication of diabetes and stands as the primary contributor to end-stage renal disease. The global prevalence of diabetic nephropathy is on the rise, however, due to its intricate pathogenesis, there is currently an absence of efficacious treatments to enhance renal prognosis in affected patients. The mammalian target of rapamycin (mTOR), a serine/threonine protease, assumes a pivotal role in cellular division, survival, apoptosis delay, and angiogenesis. It is implicated in diverse signaling pathways and has been observed to partake in the progression of diabetic nephropathy by inhibiting autophagy, promoting inflammation, and increasing oxidative stress. In this academic review, we have consolidated the understanding of the pathological mechanisms associated with four distinct resident renal cell types (podocytes, glomerular mesangial cells, renal tubular epithelial cells, and glomerular endothelial cells), as well as macrophages and T lymphocytes, within a diabetic environment. Additionally, we highlight the research progress in the treatment of diabetic nephropathy with drugs and various molecules interfering with the mTOR signaling pathway, providing a theoretical reference for the treatment and prevention of diabetic nephropathy.

Endothelin receptor antagonists in chronic kidney disease

Endothelin-1 is a potent vasoconstrictor that has diverse physiological functions in the kidney, including in the regulation of blood flow and glomerular filtration, electrolyte homeostasis and endothelial function. Overexpression of endothelin-1 contributes to the pathophysiology of both diabetic and non-diabetic chronic kidney disease (CKD). Selective endothelin receptor antagonists (ERAs) that target the endothelin A (ETA) receptor have demonstrated benefits in animal models of kidney disease and in clinical trials. In patients with type 2 diabetes and CKD, the selective ETA ERA, atrasentan, reduced albuminuria and kidney function decline. Concerns about the increased risks of fluid retention and heart failure with ERA use have led to the design of further trials to optimize dosing and patient selection. More recent studies have shown that the dual ETA receptor and angiotensin receptor blocker, sparsentan, preserved kidney function with minimal fluid retention in patients with IgA nephropathy. Moreover, combined administration of a low dose of the ETA-selective ERA, zibotentan, with the sodium-glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, enhanced albuminuria reduction and mitigated fluid retention in patients with CKD. Notably, sparsentan and aprocitentan have received FDA approval for the treatment of IgA nephropathy and treatment-resistant hypertension, respectively. This Review describes our current understanding of the use of ERAs in patients with CKD to guide their optimal safe and effective use in clinical practice.

The Role of Inflammation in the Pathogenesis of Diabetic Peripheral Neuropathy: New Lessons from Experimental Studies and Clinical Implications

Diabetic peripheral neuropathy (DPN) is one of the most frequent complications of diabetes mellitus (DM). Its pathogenesis is still not entirely clear. Inflammation is increasingly being appreciated as a key factor in its development and progression. The aim of this review was to outline current evidence from experimental research on the role of inflammation in the pathogenesis of DPN and to suggest emerging clinical implications. Beyond commonly assessed interleukins, chemokines and tumour necrosis factor alpha (TNFα), several novel underlying mechanisms and potential therapeutic targets have been unravelled. Pathogenesis is also influenced by dietary patterns, such as iron supplementation. Furthermore, the impact of the inflammasome nucleotide-binding oligomerisation domain-like receptor pyrin domain-containing protein 3 (NLPR3) is gaining importance. The same holds true for inflammatory pathways, such as the Toll-like receptor (TLR)-associated pathways or the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) pathway. SIRTuins are also of importance. DPN is associated with changes in macrophage polarisation. In addition, several metalloproteinases are emerging as contributors, although data is still limited. Finally, miRNAs (e.g. miR146a) are strongly linked with DPN by acting in several inflammatory pathways. However, we still need confirmation of preliminary research findings. It is hoped that new knowledge will lead to new therapeutic approaches, including stem cell-based or exosome-based therapies.

Vitamin D Supplementation May Prevent or Treat Deficiency After Total Knee Arthroplasty: A Retrospective Cohort Analysis

BACKGROUND

Vitamin D deficiency is associated with poorer functional outcomes and increased complication rates after total knee arthroplasty (TKA). Yet, there is no longer term study evaluating vitamin D levels and supplementation after TKA. Our study aimed to compare quantitative vitamin D levels and supplementation regimens after TKA stratified by patient sex and race.

METHODS

A retrospective cohort study of primary TKA patients at a single hospital from 2015 to 2022 was conducted. We analyzed vitamin D preoperatively and postoperatively up to 2 years. Vitamin D deficiency was defined as <30 ng/mL. A subgroup analysis was conducted in patients with vitamin D <21 ng/mL. Supplementation categories included none, low (<1,001 IU), medium (1,001 to 5,000 IU), and high (>5,000 IU).

RESULTS

A total of 400 (66.0% female) patients who underwent 430 primary TKA procedures were included, and 65.3% received supplementation. Patients who were vitamin D sufficient preoperatively demonstrated higher vitamin D levels and ability to maintain sufficiency postoperatively using low-dose supplementation compared with no supplementation ( P = 0.004). Those who were vitamin D deficient preoperatively demonstrated higher vitamin D levels postoperatively using medium to high doses ( P = 0.02). For patients who became deficient postoperatively, supplementation was associated with achieving repletion at an average of 10.2 months ( P < 0.001). Black patients demonstrated 2.8 times higher odds of having a vitamin D level less than 30 ng/mL ( P = 0.03).

CONCLUSION

Our study demonstrated that low-dose vitamin D supplementation (<1,001 IU) was beneficial for vitamin D-sufficient TKA patients to achieve higher levels and maintain vitamin D sufficiency. Vitamin D-deficient TKA patients benefitted from medium-to-high dose supplementation (1,001 to 5,000+), but only 33.7% achieved vitamin D repletion. This work highlights the need to continue vitamin D surveillance postoperatively and the need to continue vitamin D repletion.

Reducing early pregnancy loss with vitamin D3: an analysis of serum 1,25-(OH)D3 modulation and miscarriage risk

This case-control study of 124 early-pregnant women found that daily supplementation with 400 IU of vitamin D3 significantly increased serum 1,25-(OH)D3 levels and was associated with a lower incidence of threatened miscarriage. The study suggests that vitamin D3 supplementation could reduce the risk of early miscarriage and improve pregnancy outcomes by modulating immune responses and hormonal stability.

Vitamin D deficiency in Mongolian men aged 15-49 years

We aimed to estimate the prevalence of vitamin D deficiency in Mongolian men aged from 15 to 49 years at the National level as part of the Fifth National Nutrition Survey in 2016. This was a cross-sectional survey, conducted between September and November in 21 aimags of 4 economic regions of the country, and also in Ulaanbaatar. Given the regional differences in lifestyle and nutritional status, the target populations were stratified into 5 strata based on their economic region and in Ulaanbaatar, with equal samples drawn from each stratum using a cluster-randomized sampling design. A representative sample of 30 clusters [villages] was randomly selected using Probability Proportional to Size [PPS] methodology in each of the 4 regions and in Ulaanbaatar for a total of 150 cluster units. The selection of survey participants differed for the three sampling regions. Household eligibility was based on having a child 0-59 months of age, living in the household which was randomly selected from each cluster for a total of 450 households in each region. Households with a child 0-59 months of age were selected from household lists available at the kheseg or bagh level. All men 15-49 years of age who resided in the selected households were also eligible to participate in the survey. Serum concentration of 25-hydroxyvitamin D [25(OH)D] were measured using an enzyme-linked fluorescence assay in 377 men aged 15-49 years. The overall mean serum level of 25(OH)D concentration was 22.26 ± 0.48 ng/mL (95 % CI 21.31-23.21). The mean serum 25(OH)D concentrations were 19.65 ± 0.32 ng/mL (95 % CI19.01-19.82), and 33.68 ± 0.49 ng/mL (95 % CI 32.72-34.64) in vitamin D deficient, and in vitamin D sufficient subjects, respectively. The prevalence of vitamin D deficiency was 83.5 % with no significant difference in the prevalence of vitamin D deficiency by age group, economic region, area, location, education, and wealth index quintile. The prevalence of men in this study who were overweight or obese was 48.8 % and 14.6 % respectively. Although no significant difference was found between vitamin D deficiency and obesity, vitamin D deficiency was higher among men aged 30-39 and 40-49 years old by age specific analyses. The men did not take vitamin D supplements, and there is currently no vitamin D food fortification in Mongolia. The findings of this survey showed that vitamin D deficiency in men is a public health problem in Mongolia. In conclusion, vitamin D deficiency are common in Mongolian men, which indicates the need for vitamin D screening and treatment, as well as for an increased use of vitamin D supplements and for implementing vitamin D food fortification programs.